Consortium for Immunotherapeutics against Emerging Viral Threats

摘要 我们最近发起了冠状病毒免疫治疗联盟，这是一项国际努力 对针对SARS-CoV-2尖峰病毒的主要治疗性抗体候选进行并列分析 来自多个大陆的一系列大小公司和学术实验室贡献的蛋白质。Covic 提供在同一化验下对领先的候选治疗方法进行并列分析的机会 条件，以及关于活动的更广泛、更深入的数据集的实时协作组装 针对SARS-CoV-2的抗体的效力超过了任何单一发现工作所能组装的效力。这个 目前资助的Covic研究主要集中在免疫球蛋白治疗性抗体Fab区域的特征：结合 和机械中和，并仅分析来自原SARS-CoV武汉参考毒株的尖峰。 2.拟议的补充内容将为CoC中目前缺失的关键组件提供支持 但这是加速抗体临床进展所必需的，这些抗体将是安全、有效和提供 持久的保护。我们将确定Fc介导的治疗性抗体的活性、可能性或风险 从临床候选人的增强，以及哪些表位和位置和易感性突变逃逸。 由此产生的大量信息将为早期和下一代抗体疗法提供信息，并将确保 治疗方法是已知的，它对新出现的病毒变体有反应。

ABSTRACT We recently galvanized the Coronavirus Immunotherapeutic Consortium, CoVIC, an international effort to conduct side-by-side analyses of leading therapeutic antibody candidates against the SARS-CoV-2 Spike protein contributed by a range of large and small companies and academic labs on multiple continents. CoVIC provides an opportunity for side-by-side analysis of the leading therapeutic candidates under the same assay conditions, as well as real-time collaborative assembly of a broader, deeper dataset on the activities and potencies of antibodies against SARS-CoV-2 than could be assembled by any single discovery effort alone. The currently funded CoVIC studies focus largely on characteristics of the Fab region of the IgG therapeutic: binding and mechanical neutralization, and analyze only spike from the original Wuhan reference strain of SARS-CoV- 2. The proposed supplement will provide support for critical components that are currently missing from CoVIC but which are needed to accelerate clinical advancement of antibodies that will be safe, efficacious and offer durable protection. We will determine Fc-mediated activities of the therapeutic antibodies, the likelihood or risk of enhancement from clinical candidates, and which epitopes and sites of and susceptibility to mutagenic escape. The resulting body of information will inform early and next-generation antibody therapies and will ensure that therapeutics are known which are responsive to emerging viral variants.